Travere Therapeutics, Inc. (TVTX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Travere Therapeutics, Inc. currently loses $23.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Travere Therapeutics’ third fiscal quarter of 2026 paired a revenue beat with an earnings miss when it reported results on November 2, 2026, as revenue of $224.6 million topped the $195.3 million estimate, +15%, while EPS of -$0.55 trailed the -$0.10 estimate by -$0.45. Revenue rose 36.2% to about $224.6 million, up from about $164.9 million a year ago, reflecting contributions from its marketed portfolio led by FILSPARI and Thiola-based treatments. Profitability remained negative, with operating income of roughly -$68.1 million translating to an operating margin of about -30%, and net income came in at roughly -$52.3 million versus about $25.7 million a year earlier. Despite the GAAP loss, the company generated operating cash flow of about $74.7 million during the quarter. For the next period, consensus calls for EPS of $0.45 on revenue of $234.6 million.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing and commercializing therapies for rare kidney and metabolic diseases, with $490.7 million in revenue in FY2025. Its business centers on specialty medicines for small patient populations, led by FILSPARI for rare kidney disorders and Thiola-based treatments for cystinuria.
Today's Snapshot
TVTX closed 1.7% below yesterday's close, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level.
Trading Volume
Below 10d avg (1.2M)
830.2K
vs S&P 500 Today
Underperforming Market
-1.42%
Updated: November 18, 2026 at 21:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$47.44 - $54.01Sell
- RSI (14)43.88Neutral
- Stochastic %K (14, 3, 3)65.54Neutral
- MACD Level (12, 26)-1.00Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.